Teva Pharmaceuticals Industries Ltd., announced at the JP Morgan Healthcare Conference that it has successfully completed recruitment in Europe and the United States of the planned 640 participants in the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749). ). The results of the study are expected in the second half of 2024.
The drug candidate mdc-TJK consists of a long-acting monthly subcutaneous injection of olanzapine – an atypical antipsychotic – for the treatment of schizophrenia. mdc-TJK may be the first long-acting formulation of olanzapine with a favorable safety profile.
Teva remains fully responsible for the development and commercialization of olanzapine LAI globally.
MedinCell could receive up to $117 million in milestone payments for the development and commercialization of mdc-TJK over the next several years, and is also eligible for royalties on all net sales.